# THE SPECTRUM OF NON-AIDS DEFINING MALIGNANCIES: 431 CASES

Dalla Pria A., Flook M., Williams J., Goode E., Berg L., Newsom-Davis T., Nelson M., Bower M.

Department of HIV/Oncology Chelsea and Westminster Hospital NHS Foundation Trust

### **BACKGROUND**


The incidence of non-AIDS defining malignancies (NADM) has steadily risen in the post-HAART era and a spectrum of malignancies has been observed in cohorts that may reflect the etiology of malignancy in the immunosuppressed.


#### **METHODS**


We have prospectively collected clinical data including non-AIDS defining malignancy in a prospective database for our cohort of patients since 1986


Population features:	
Total number of patients with NADM since 1986	431
Sex (%): M - F	94% - 6%
Mean age at NADM dx	48ys


#### **RESULTS**












The 5 year OS is higher in the HAART era compared to the pre HAART era (65 & 43%, log rank p=0.004)



## CONCLUSIONS

-The increasing burden of NADM has been well documented and we confirm this in our sizeable cohort -Of 431 NADMs 61% may be attributed to oncogenic infections

-As with the AIDS defining cancers, the survial of NADM has improved in the post HAART era